220 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
with moderate-to-severe asthma. The data are anticipated to be presented at the upcoming American Thoracic Society International Conference.
frexalimab (CD40L
6-K
EX-99.2
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
and internationally. Being active in charity work for many years, Jean-Baptise decided to devote the next stage of his career to giving back to society
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
multiple myeloma. The results were presented at the American Society of Hematology (ASH) 2023 annual meeting.
The study evaluating the efficacy … at the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2023 annual conference. Additionally, the full data set was simultaneously published
6-K
EX-99.3
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
) were presented during the oral plenary session (#4) at the American Society of Hematology (ASH) Annual Meeting by Francesca Gay, Associate Professor
6-K
EX-99.1
SNY
Sanofi
27 Sep 23
Current report (foreign)
6:06am
to positively impact society by tackling climate change and its consequences for human health.
Ramping up adaptation efforts and initiatives to address … driven by the ambition to make a sustainable positive impact for our people, our communities and society overall. This is why we are taking the initiative
6-K
EX-99.1
zluxl8i74afz jicj
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
EX-99.1
x0bflz3
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
7dbwzqf gpk
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
kx5tuhpvqx9owbe6y54f
5 Jul 23
Current report (foreign)
8:43am
6-K
EX-99.2
wl6rn
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
o7fkhg7sllfzrf
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
8vq vwsbp48k
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
8xhkegoztlx9g
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.2
5nby0hq zqg5pdcj6j
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
dk6vnzdwd7
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.1
hpzr6sgjr836uubmh
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
8bmy 3jdrg
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.2
ery6i
13 Jul 22
Current report (foreign)
1:40pm
6-K
EX-99.1
kprek6a0
13 Jul 22
Current report (foreign)
1:40pm
6-K
EX-99.2
fyqqlgb8
17 May 22
Current report (foreign)
3:20pm